Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping data

[cafead]

via In a phase 3 trial, Lorbrena showed it could outdo predecessor Xalkori at keeping lung cancer progression at bay. The company is keeping detailed results under wraps for now, but it’ll be sharing them with global regulators in hopes of moving the therapy earlier into treatment.

article source